Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 14/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 13/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 9/20 | 1.00 |
| ▸ | TTR | P02766 | 2/20 | 0.66 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enofelast SCHEMBL636264 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2ALOX5TTRNFE2L2 | |
| SCHEMBL1824103 | 0.82 | PTGS1 (0.74) | PTGS1PTGS2ALOX5TTR | |
| SCHEMBL1824102 | 0.82 | PTGS1 (0.74) | PTGS1PTGS2ALOX5TTR | |
| SCHEMBL12644662 | 0.81 | TTR (0.76) | PTGS1PTGS2ALOX5TTR | |
| SCHEMBL18130097 | 0.79 | PTGS1 (0.67) | PTGS1PTGS2ALOX5NFE2L2 | |
| SCHEMBL12644239 | 0.79 | PTGS1 (1.00) | PTGS1PTGS2ALOX5TTR | |
| SCHEMBL10946633 | 0.79 | PTGS1 (1.00) | PTGS1PTGS2ALOX5TTR | |
| SCHEMBL18130096 | 0.79 | PTGS1 (0.67) | PTGS1PTGS2ALOX5NFE2L2 | |
| SCHEMBL3970919 | 0.78 | TNFRSF1A (0.65) | PTGS1PTGS2ALOX5 | |
| SCHEMBL3970921 | 0.78 | TNFRSF1A (0.65) | PTGS1PTGS2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 448 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | claimed |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-25 | — | — | US | claimed |
| EP-4356912-A2 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | Techfields Pharma Co., Ltd. (CN) | 2024-04-24 | — | — | EP | claimed |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-11 | — | — | US | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-20210121440-A1 | ACNE TREATMENT | ZOUBOULIS CHRISTOS C (DE) | 2021-04-29 | — | — | US | claimed |
| US-20190298689-A1 | ACNE TREATMENT | ZOUBOULIS CHRISTOS C (DE) | 2019-10-03 | — | — | US | claimed |
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | claimed |
| US-20180086778-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | NEUROGESX, INC. | 2018-03-29 | — | — | US | claimed |
| US-20170296509-A1 | ACNE TREATMENT | ZOUBOULIS CHRISTOS C (DE) | 2017-10-19 | — | — | US | claimed |
| EP-1385505-A2 | ACNE TREATMENT | Zouboulis, Christos (DE) | 2004-02-04 | — | — | EP | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2002089791-A2 | ACNE TREATMENT WITH LIPOOXIGENASE INHIBITORS | ZOUBOULIS CHRISTOS C (DE) | 2002-11-14 | — | — | WO | claimed |
| US-20020143033-A1 | Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | G.D. SEARLE & CO. | 2002-10-03 | — | — | US | claimed |
| EP-0888127-B1 | COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS | SEARLE & CO (US) | 2001-12-12 | — | — | EP | claimed |
| US-6136839-A | USING A SULFONE OR SULFOAMIDE BENZENE COMPOUND | G. D. SEARLE & CO. (US) | 2000-10-24 | — | — | US | claimed |
| EP-0888127-A1 | COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1999-01-07 | — | — | EP | claimed |
| EP-0833622-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1997029776-A1 | COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-08-21 | — | — | WO | claimed |
| WO-1996041626-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | PTGS1 92/4885PTGS2 146/4885ALOX5 302/4885 |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | PTGS1 92/4885PTGS2 146/4885ALOX5 302/4885 |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | PTGS1 92/4885PTGS2 146/4885ALOX5 302/4885 |
| US-20020143033-A1 | Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | ALOX5, ALOX15B, ALOX15 | PTGS1 11/4885PTGS2 6/4885ALOX5 1/4885 |
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | CA6, CA7, CA4 | PTGS1 529/4885PTGS2 768/4885ALOX5 946/4885 |
| US-20180086778-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | PTGS1 529/4885PTGS2 768/4885ALOX5 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.